Nicotinamide Mononucleotide (NMN) is a naturally occurring molecule that serves as a direct precursor to Nicotinamide Adenine Dinucleotide (NAD+), a crucial coenzyme involved in fundamental biological processes like metabolism, DNA repair, and gene expression (sirtuins). By supplementing NMN, the goal is to boost cellular NAD+ levels, which decline with age, thereby promoting cellular health and potentially mitigating age-related dysfunction. Prominent research groups include David Sinclair's lab at Harvard Medical School and Shin-ichiro Imai's lab at Washington University School of Medicine, alongside various nutraceutical companies. NMN is currently widely available as a dietary supplement, with clinical trials ongoing to establish efficacy and safety in humans. A significant study published in Science in 2018 demonstrated that NMN improved metabolic health and exercise capacity in aged mice. Unlike direct NAD+ infusions, NMN offers an oral, non-invasive method for NAD+ elevation.
Editorial check
How this page is checked
Source trail
Editorial source pending
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It Matters
Declining NAD+ levels are linked to a host of age-related metabolic disorders, cardiovascular issues, and neurodegeneration, affecting billions and contributing to a massive disease burden. Widespread NMN use could lead to improved energy levels, better metabolic health, and enhanced cognitive function in older adults, extending their period of active, independent living. Supplement manufacturers and longevity clinics would benefit significantly, while some traditional pharmaceutical treatments for metabolic syndrome might see reduced demand. The main barriers include robust, large-scale human clinical trials to definitively prove long-term efficacy and safety, and regulatory clarity regarding its classification (supplement vs. drug). Initial human trials for specific outcomes are expected within 2-5 years, with broad acceptance contingent on compelling data. Companies like Elysium Health and ChromaDex (focusing on NR, another NAD+ precursor) are key players, with strong interest from consumers in the US, Japan, and China. A second-order consequence might be a global debate on the ethics of life extension and equitable access to such technologies, exacerbating existing health disparities if not carefully managed.
Development Stage
Related
Scrintal
Scrintal is a visual knowledge canvas and note-taking tool developed by a startup, designed to help users think spatially and connect ideas on an infinite…
Jasper
Jasper is an AI content platform developed by Jasper AI, designed to help individuals and teams generate high-quality written content quickly and efficiently…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.